What is Atea Pharmaceuticals?
Headquartered in Boston, Atea Pharmaceuticals is a clinical-stage biopharmaceutical organization dedicated to the discovery and development of oral antiviral agents. The company's core focus lies in addressing viral infections through innovative therapeutic candidates, most notably its lead asset, AT-527, currently undergoing Phase 3 clinical evaluation for COVID-19. By leveraging a robust scientific framework and strategic partnerships, such as its collaboration with MSD International for HCV treatments, Atea maintains a competitive edge in the antiviral market. The firm's operational model integrates rigorous fundamental research with a scalable development strategy, positioning it as a key player in the evolving landscape of life sciences and biotechnology.
How much funding has Atea Pharmaceuticals raised?
Atea Pharmaceuticals has raised a total of $591M across 6 funding rounds:
Series A
$20M
Unspecified
$20.8M
Unspecified
$27.6M
Series B
$7.6M
Series D
$215M
Stock Offering
$300M
Series A (2014): $20M, investors not publicly disclosed
Unspecified (2016): $20.8M, investors not publicly disclosed
Unspecified (2018): $27.6M, investors not publicly disclosed
Series B (2019): $7.6M, investors not publicly disclosed
Series D (2020): $215M backed by Redmile Group, Ally Bridge Group, Rock Springs Capital, Omega Funds, Bain Capital LP, T. Rowe Price Associates, Adage Capital Management, Morningside Ventures, Sectoral Asset Management, RA Capital Management , LLC, Cormorant Asset Management, and Perceptive Advisors
Stock Issuance/Offering (2020): $300M with participation from Undisclosed
Key Investors in Atea Pharmaceuticals
Redmile Group
Redmile Group LLC is a specialized venture capital and private equity firm focused on high-growth opportunities within the healthcare and life sciences sectors.
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm that specializes in high-impact life science innovation, managing significant capital to address unmet medical needs.
Perceptive Advisors
Founded in 1999, Perceptive Advisors is a prominent investment firm managing billions in assets, specifically focused on funding innovative healthcare and life sciences technologies.
What's next for Atea Pharmaceuticals?
With the recent capital injection, Atea Pharmaceuticals is well-positioned to advance its late-stage clinical trials and expand its therapeutic portfolio. The strategic focus will likely remain on the successful execution of the SUNRISE-3 trial and the continued development of its combination therapies for hepatitis C. As the company navigates the complexities of regulatory approval and commercialization, the sustained support from institutional investors provides the necessary runway to scale its manufacturing capabilities and broaden its market reach. Future growth will be contingent upon the clinical validation of its pipeline and the successful integration of its protease inhibitor programs into the broader antiviral market.
See full Atea Pharmaceuticals company page
